GenKyoTex

GenKyoTex is a product-driven biopharmaceutical company dedicated to the development of innovative therapeutics blocking the source of production of oxygen radicals in a specific manner to meet unmet medical needs. GenKyoTex is the world leader for the development of inhibitors of NADPH oxidases.

The involvement of reactive oxygen species (ROS) in fibrosis, pulmonary hypertension, cancer, diabetes, atherosclerosis, and vascular injury, as well as in neurodegenerative pathologies including amyotrophic lateral sclerosis and Alzheimer's diseases was proven by different worldwide leading academic groups paving the way to a new therapeutic approach against these diseases. GenkyoTex, the NOX company is clearly best positioned to open this new market.

For more information, please visit www.genkyotex.com